{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:47:38Z","timestamp":1788317258673,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["251750"],"award-info":[{"award-number":["251750"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-165845"],"award-info":[{"award-number":["PJT-165845"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jclinepi.2026.112149","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:17:52Z","timestamp":1768868272000},"page":"112149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Early-phase trial efficacy and safety effect estimates regress upon testing in phase 3 trials"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-5217","authenticated-orcid":false,"given":"Angela","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Vigneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Sefranek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6093","authenticated-orcid":false,"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1614-6779","authenticated-orcid":false,"given":"Jonathan","family":"Kimmelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jclinepi.2026.112149_bib1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/cpt.1251","article-title":"Weighing of evidence by health technology assessment bodies: Retrospective study of reimbursement recommendations for conditionally approved drugs","volume":"105","author":"Vreman","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112149_bib2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1377\/hlthaff.2017.1580","article-title":"Precision medicines have faster approvals based on fewer and smaller trials than other medicines","volume":"37","author":"Pregelj","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112149_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cpt.900","article-title":"European marketing authorizations granted based on a single pivotal clinical trial: the rule or the exception?","volume":"104","author":"Morant","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jclinepi.2026.112149_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.04.001","article-title":"Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020)","volume":"159","author":"Ribeiro","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jclinepi.2026.112149_bib5","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1200\/OP.20.00131","article-title":"Safety and evidence of off-label use of approved drugs at the nNational Cancer Center Hospital in Japan","volume":"17","author":"Bun","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112149_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ijc.33215","article-title":"Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: is there evidence of progress?","volume":"148","author":"Desai","year":"2021","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112149_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2010.31.6414","article-title":"Level of scientific evidence underlying recommendations arising from the national Comprehensive Cancer Network Clinical Practice Guidelines","volume":"29","author":"Poonacha","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jclinepi.2026.112149_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-018-0016-0","article-title":"The paradox of precision medicine","volume":"15","author":"Kimmelman","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jclinepi.2026.112149_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112149_bib10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/bcp.14237","article-title":"Efficacy gap between phase II and subsequent phase III studies in oncology","volume":"86","author":"Vreman","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jclinepi.2026.112149_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2019.08.006","article-title":"Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting","volume":"121","author":"Liang","year":"2019","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.jclinepi.2026.112149_bib12","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.ejca.2015.08.004","article-title":"Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome","volume":"51","author":"Monzon","year":"2015","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.jclinepi.2026.112149_bib13","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1200\/JCO.2005.06.679","article-title":"Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens","volume":"23","author":"Zia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jclinepi.2026.112149_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050201","article-title":"Why current publication practices may distort science","volume":"5","author":"Young","year":"2008","journal-title":"PLoS Med"},{"issue":"16","key":"10.1016\/j.jclinepi.2026.112149_bib15","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1001\/jama.2012.13444","article-title":"Empirical evaluation of very large treatment effects of medical interventions","volume":"308","author":"Pereira","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2026.112149_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jclinepi.2023.03.028","article-title":"Bypassing phase 2 in cancer drug development erodes the risk\/benefit balance in phase 3 trials","volume":"158","author":"Moyer","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jclinepi.2026.112149_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112149_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J of Cancer"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112149_bib20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in cochrane reviews: the ROBES meta-epidemiologic study","volume":"187","author":"Savovi\u0107","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.jclinepi.2026.112149_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159267","article-title":"Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies","volume":"11","author":"Page","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinepi.2026.112149_bib22","author":"Carlisle"},{"key":"10.1016\/j.jclinepi.2026.112149_bib23","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jclinepi.2026.112149_bib24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","article-title":"Defining the Most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis","volume":"4","author":"Ritchie","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jclinepi.2026.112149_bib25","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-17-1902","article-title":"Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials","volume":"24","author":"Mushti","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jclinepi.2026.112149_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jclinepi.2026.112149_bib27","series-title":"Regression of Efficacy and Safety Effects As Treatments Advance from Phase 2 to Phase 3","author":"Nelson","year":"2022"},{"key":"10.1016\/j.jclinepi.2026.112149_bib28","author":"Friedman"},{"issue":"3","key":"10.1016\/j.jclinepi.2026.112149_bib29","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1097\/PTS.0000000000000911","article-title":"Challenges and barriers to adverse event reporting in clinical trials: a children's oncology group report","volume":"18","author":"Miller","year":"2022","journal-title":"J Patient Saf"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112149_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jclinepi.2026.112149_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jclinepi.2026.112149_bib32","article-title":"Publication bias in clinical trials due to statistical significance or direction of trial results","volume":"2009","author":"Hopewell","year":"2009","journal-title":"Cochrane Database of Syst Rev"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112149_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jnci\/djx232","article-title":"Magnitude of clinical benefit of cancer drugs approved by the US food and drug administration","volume":"110","author":"Tibau","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jclinepi.2026.112149_bib34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jclinepi.2026.112149_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034306","article-title":"Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study","volume":"10","author":"Carlisle","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jclinepi.2026.112149_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.0217","article-title":"Timing of confirmatory trials for drugs granted accelerated approval based on surrogate measures from 2012 to 2021","volume":"4","author":"Deshmukh","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"5","key":"10.1016\/j.jclinepi.2026.112149_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3410","article-title":"Analysis of postapproval clinical trials of therapeutics approved by the US food and drug administration without clinical postmarketing requirements or commitments","volume":"2","author":"Skydel","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435626000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:14:39Z","timestamp":1778505279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435626000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"alternative-id":["S0895435626000211"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112149","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-phase trial efficacy and safety effect estimates regress upon testing in phase 3 trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2026.112149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112149"}}